Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.
Also called NCT01819272
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- Elcelyx Therapeutics, Inc.
- Registry
-
NCT01819272
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01819272. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2013-09 (actual). Results posted on 2015-09-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Met DR
- Intervention (Drug)
- Met XR
- Intervention (Drug)
- Placebo
- Lead sponsor
- Elcelyx Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct01819272- Content hash
9e50830f062d01d94c8f6334336454f4c6e68613382a984e11e7fac0a33b28ab